We need to start thinking of digital as part of a marketing plan instead of The Plan.
Big Pharma doesn't hire big agencies purely because of cost efficiencies. There's more to it than that. Sometimes companies choose their partners because there's a perception that a big "established" agency with global recognition is better and safer. If a brand succeeds, they can share in the glory. If a brand fails, they can find comfort in knowing that they didn't choose an unknown company. To them, size does matter. It helps mitigate risk.
At times digital marketing seems more like a bunch of tactics looking for a cohesive strategy. We need to start thinking of digital as part of a marketing plan instead of The Plan and build the relationships with our stakeholders first before considering relationships with patients.
It's too bad this type of thinking still exists. Perhaps ten to fifteen years ago there was some truth to this. But no longer. Technology and strategic alliances are great equalizers. They give independent agencies the ability to compete on the same level as large holding companies. We can deliver innovative thinking, creativity, and success just as well as the large bureaucratic giants. We can offer a team of senior people around the globe, nimbleness, and enthusiasm that can't easily be duplicated by a large bureaucratic system.
Topin and Associates been serving as the lead agency for several of its global clients and turning to its member partners for support and execution. For these clients, it didn't matter that we were not part of a large public bureaucracy. What mattered was that we helped deliver impact for their brands with high passion, energy, and efficiency.
Perceived value and customer experience are precisely what branding is all about. The customer's relationship with the brand—whether it's at the level of the healthcare professional or at the patient level—includes interaction with the sales force, the product, and obviously, the effects and results that the product delivers.
More and more pharmaceutical and healthcare companies are approaching product launches on a global basis. Technology and digital marketing has helped make this possible, according to Tony Chant, founder of the Eurocom Healthcare Communications Network.The alliance offers global clients choices. No longer are they limited to a small group of networks. Now they can choose to select a holding company with affiliates, or a partnership of nimble agencies. Both types of affiliations demonstrate their strengths and opportunities and leverage their "feet on the ground" in various markets. With a level playing field, clients can choose which type of network is best for their brands.
Established in 1996, the European Network figured that there was stretch in numbers. Each member has an opportunity to build strong global brands while remaining independent, flexible, creative, and efficient. What began as one or two companies blossomed to many member agencies. The full-service Network's presence reaches across the UK, France, Germany, Spain, Italy, Austria, and the U.S. Members share a kind of singularity of focus.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.